Thank you to our speakers, sponsors, and delegates who joined us for the summit! If you are interested in the 2025 event, please get in touch at info@hansonwade.com
Boost Selectivity, Overcome Resistance & Leverage Combination Strategies for Safe & Efficacious Hippo Pathway Targeted Therapies Towards Clinical Success in Oncology, Regenerative Medicine & Beyond
Ran November 20-21, 2024 | Virtual Summit
Welcome to the 3rd Hippo Pathway Targeted Drug Development Summit
Igniting Novel YAP, TAZ & TEAD Modulators Towards Clinical Validation
The field of Hippo Pathway targeted drugs is seeing a surge of activity, with new clinical data being generated everyday and novel combinations being tested. The 3rd Hippo Pathway Targeted Drug Development Summit was built alongside industry experts from companies like Vivace Therapeutics, Orion Pharma, Insilico Medicine and more. It returned as the premier event for Hippo industry leaders, focusing on developing innovative, safe, and effective therapies in oncology, fibrosis, and beyond.
Over 20 global Hippo experts joined to advance YAP, TAZ, and TEAD modulators towards clinical success – all from the comfort of their screens! The event served as a virtual hub where 80+ Hippo experts from across the globe gathered for data-led presentations, deep-diving panels, and interactive roundtables to advance the Hippo industry forward.
Our World-Class Speaker Faculty for 2024 Included:
Topics That Were Brand New for 2024:
- Minimizing Off-Target Toxicity: Optimizing patient selection with the latest clinical data on Hippo-targeting drugs from Vivace Therapeutics and Crossignal Therapeutics.
- Fast-Tracking Your IND Process: Delving into case studies showcasing in vivo efficacy in mesothelioma models and cutting-edge immunotherapy combinations from Insilico Medicine, Tyk Medicines, and Etern Therapeutics.
- Mastering Hippo Pathway Inhibition: Discovering breakthrough covalent drugs and targeted degraders from BridGene Bioscience and the University of Florida, aimed at achieving sustained Hippo pathway inhibition.
- Unlocking Powerful Combination Therapies: Uncovering strategies to overcome Hippo-driven resistance to KRAS, MAPK, and EGFR inhibitors with insights from the University of Toledo and University of Torino.
- Enhancing Predictive Accuracy: Learning how preclinical models from Albany Medical College, University of Edinburgh, and Cleveland Clinic are reliably predicting patient sensitivity and clinical outcomes.
Other events in the Small Molecules & TPD World Series
